Market capitalization | $1.59b |
Enterprise Value | $1.13b |
P/E (TTM) P/E ratio | 73.55 |
EV/FCF (TTM) EV/FCF | 18.86 |
EV/Sales (TTM) EV/Sales | 4.09 |
P/S ratio (TTM) P/S ratio | 5.75 |
P/B ratio (TTM) P/B ratio | 2.70 |
Revenue growth (TTM) Revenue growth | 19.36% |
Revenue (TTM) Revenue | $277.25m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
5 Analysts have issued a Dynavax Technologies Corporation forecast:
5 Analysts have issued a Dynavax Technologies Corporation forecast:
Dec '24 |
+/-
%
|
||
Revenue | 277 277 |
19%
19%
|
|
Gross Profit | 228 228 |
25%
25%
|
|
EBITDA | 5.98 5.98 |
122%
122%
|
EBIT (Operating Income) EBIT | -2.07 -2.07 |
94%
94%
|
Net Profit | 27 27 |
527%
527%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.
Head office | United States |
CEO | Ryan Spencer |
Employees | 405 |
Founded | 1996 |
Website | www.dynavax.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.